Evidence map›Paper›PMID 38191687›Full record

ReviewCell and tissue banking2024

An important detail that is still not clear in amniotic membrane applications: How do we store the amniotic membrane best?

Mehmet Gurdal, Ilayda Korkmaz, Ozlem Barut Selver

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cell and tissue banking, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mehmet GurdalLimbustem R&D Medical Products Ltd., Izmir, Turkey.ORCID http://orcid.org/0000-0003-1226-1737
Ilayda KorkmazDepartment of Ophthalmology, Faculty of Medicine, Ege University, 35040, Bornova, Izmir, Turkey.ORCID http://orcid.org/0000-0001-8043-8632
Ozlem Barut SelverLimbustem R&D Medical Products Ltd., Izmir, Turkey. ozlembarutselver@gmail.com.ORCID http://orcid.org/0000-0003-3333-3349

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of fresh amniotic membrane (AM) is not a viable option, as it has many disadvantages. Preserving the AM reduces the risk of cross-infection and maintains its effectiveness for a long time. In order to maximize the therapeutic effects of the AM, the basic need is to preserve its vitality and the bioactive molecules it contains. However, the effect of preservation procedures on cell viability and growth factors is a still matter of debate. Optimum preservation method is expected to be cost-effective, easily-accessible, and most importantly, to preserve the effectiveness of the tissue for the longest time. However, each preservation technique has its advantages and disadvantages over the other, and each one compromises the vitality and bioactive molecules of the tissue to some extent. Therefore, the best method of preservation is still controversial, and the question of 'how to preserve the AM best?' has not yet been definitively answered.

Indexed as

AmnionCryopreservationAmniotic membraneCryopreservationLyophilizationPreservation methods

Identifiers

PMID38191687

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.